Novo Nordisk A/S
NYSE:NVODrug Manufacturers - General
-$0.48 today
- Market cap
- $173.82B
- Beta
- 0.35
- P/E (TTM)
- 10.2
- EPS (TTM)
- $27.45
- Dividend yield
- 4.18%
Volume 16.12M
Average 16.05M
NVO Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Novo Nordisk A/SNYSE: NVO
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures dips below year-ago levels
Q2 FY2026 capital expenditures of DKK 12.8B (cash outflow) fell 21.3% year over year, behind the +40.3% change in trailing-twelve-month capital expenditures. Sequentially, it rose 6.3% from the prior quarter. Over 3 fiscal years it compounded at +82.8% a year.
Context
- Capital expenditures amounted to 29.2% of revenue in FY2025, up 11.5 pp from a year earlier.
- Capital expenditures grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -21.3% toward the trailing-twelve-month pace of +40.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
DKK · from the cash flow
- Latest · FY2025
- (90.11B) DKK
- Year-over-year change
- -75.6%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (90.11B) | -75.6% |
| FY2024 | 2024-12-31 | (51.31B) | -31.9% |
| FY2023 | 2023-12-31 | (38.9B) | -163.6% |
| FY2022 | 2022-12-31 | (14.75B) | -99.8% |
| FY2021 | 2021-12-31 | (7.39B) | — |
Capital Expenditures vs competitors
How NVO compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +40.3% is the 2nd highest of 9, against a peer median of -4.9%.
- Capital expenditures amounts to 25.5% of revenue for NVO, versus a peer median of 5.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 84.09B DKK | +40.3% | +82.8% | 25.5% | |
| LTM Jun 2026 | $8.03B USD | -26.9% | +38.0% | 10.1% | |
| LTM Sep 2026 | $5.57B USD | +8.6% | +6.4% | 5.6% | |
| LTM Sep 2026 | $4.01B USD | -28.0% | +31.9% | 6.5% | |
| LTM Jun 2026 | $3.9B USD | +2.4% | -2.1% | 5.9% | |
| LTM Jun 2026 | €2.52B EUR | — | -1.8% | 5.2% | |
| LTM Jun 2026 | $2.42B USD | -12.1% | -6.7% | 3.8% | |
| LTM Jun 2026 | $2.3B USD | +63.6% | +25.7% | 6.0% | |
| LTM Jun 2026 | £1.76B GBP | -42.4% | -2.2% | 5.3% | |
| LTM Jun 2026 | $1.3B USD | +24.2% | +20.4% | 2.0% | |
| Peer median (excluding NVO) | — | -4.9% | +6.4% | 5.6% | |
Competitors are the stored peer set for NVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 47.76B | 55.53B | 83.68B | 100.99B | 102.43B |
| Depreciation & Amortization | 6.03B | 7.36B | 9.41B | 19.11B | 21.98B |
| Deferred Income Tax | 11.32B | 13.54B | 20.99B | 26.2B | 28.11B |
| Stock-Based Compensation | 1.04B | 1.54B | 2.15B | 2.29B | 0 |
| Change in Working Capital | (8.66B) | (5.54B) | (12.25B) | 2.59B | 3.74B |
| Accounts Receivables | (12.91B) | (10.82B) | (14.21B) | (14.31B) | 0 |
| Inventory | (1.09B) | (4.77B) | (7.42B) | (9.04B) | 0 |
| Accounts Payables | 3.15B | 6.72B | 10.02B | 3.24B | 0 |
| Other Working Capital | 2.19B | 3.34B | (631M) | 22.7B | 3.74B |
| Other Non-Cash Items | (2.49B) | 6.46B | 4.92B | (30.21B) | (37.16B) |
| Operating Cash Flow | 55B | 78.89B | 108.91B | 120.97B | 119.1B |
| Capital Expenditures | (7.39B) | (14.75B) | (38.9B) | (51.31B) | (90.11B) |
| Acquisitions (Net) | (18.28B) | (7.08B) | 0 | (82.16B) | 1B |
| Purchases of Investments | (7.11B) | (9.74B) | (13.29B) | (19.81B) | (723M) |
| Sales of Investments | 1.17B | 6.65B | 8.29B | 24.39B | 10.67B |
| Other Investing Activities | 4M | (2.61B) | (13.09B) | (4.15B) | (29.97B) |
| Investing Cash Flow | (31.61B) | (24.92B) | (43.89B) | (128.9B) | (79.16B) |
| Debt Repayment | 15.47B | (2.41B) | (1.47B) | 73.06B | 24.74B |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (19.45B) | (24.09B) | (29.92B) | (20.18B) | (1.39B) |
| Dividends Paid | (21.52B) | (25.3B) | (31.77B) | (44.14B) | (51.76B) |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | (25.49B) | (51.8B) | (63.16B) | 8.74B | (28.41B) |
| Effect of Forex Changes | 591M | (238M) | (119M) | 455M | (727M) |
| Net Change in Cash | (1.51B) | 1.93B | 1.74B | 1.26B | 10.81B |
| Free Cash Flow | 47.62B | 64.13B | 70.01B | 69.66B | 28.99B |
Novo Nordisk A/S
NYSE:NVO
Intrinsic Alpha fair value
Locked
Current Price
$39.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.